Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Hydronephrosis 1Carcinoma, Renal Cell 1Breast Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 3Oncolytic Virotherapy 3Magnetic Resonance Spectroscopy 3Specimen Handling 2Radiotherapy 2Nivolumab 2Irinotecan 2Doxorubicin 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1pertuzumab 1perflutren 1palbociclib 1olaparib 1niraparib 1montelukast 1eribulin 1entrectinib 1cobimetinib 1camrelizumab 1atezolizumab 1apatinib 1alovudine 1alectinib 1X-Rays 1Vinorelbine 1Vincristine 1Vemurafenib 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Sarcoma × Disulfides × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡